

# William T Curry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6241085/publications.pdf>

Version: 2024-02-01

88  
papers

4,888  
citations

147801

31  
h-index

98798

67  
g-index

88  
all docs

88  
docs citations

88  
times ranked

8808  
citing authors

#	ARTICLE	IF	CITATIONS
1	The New England Neurosurgical Society: growth and evolution over 70 years. <i>Journal of Neurosurgery</i> , 2023, 138, 261-269.	1.6	1
2	Reversal of Intracranial Hypertension-Related Pseudomeningocele after Venous Sinus Stenting. , 2022, 2, .		0
3	Implications of IDH mutations on immunotherapeutic strategies for malignant glioma. <i>Neurosurgical Focus</i> , 2022, 52, E6.	2.3	10
4	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
5	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18
6	Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. <i>Neuro-Oncology</i> , 2022, 24, 2180-2189.	1.2	1
7	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2030-2030.	1.6	3
8	Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2037-2037.	1.6	3
9	Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 252-266.	0.8	28
10	<i>TERT</i> Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 169-178.	7.0	50
11	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 385-391.	2.2	4
12	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	1.4	13
13	Case 10-2021: A 70-Year-Old Man with Depressed Mood, Unsteady Gait, and Urinary Incontinence. <i>New England Journal of Medicine</i> , 2021, 384, 1350-1358.	27.0	0
14	Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting. <i>Frontiers in Pharmacology</i> , 2021, 12, 660841.	3.5	6
15	Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system. <i>Journal of Neuro-Oncology</i> , 2021, 153, 331-342.	2.9	3
16	Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy. <i>Clinical Neurophysiology</i> , 2021, 132, 1416-1432.	1.5	6
17	Neurophysiologic Mapping of Thalamocortical Tract in Asleep Craniotomies: Promising Results From an Early Experience. <i>Operative Neurosurgery</i> , 2021, 20, 219-225.	0.8	5
18	Navigable Channel-Based Trans-Sulcal Resection of Third Ventricular Colloid Cysts: A Multicenter Retrospective Case Series and Review of the Literature. <i>World Neurosurgery</i> , 2020, 133, e702-e710.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Atypical Histopathological Features and the Risk of Treatment Failure in Nonmalignant Meningiomas: A Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2020, 133, e804-e812.	1.3	4
20	IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. <i>OncolImmunology</i> , 2020, 9, 1806662.	4.6	26
21	Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 465-470.	1.9	118
22	Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. <i>International Forum of Allergy and Rhinology</i> , 2020, 10, 798-805.	2.8	284
23	A Common Rule for Resection of Glioblastoma in the Molecular Era. <i>JAMA Oncology</i> , 2020, 6, 503.	7.1	3
24	MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with baviximab, radiation, and temozolomide.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2546-2546.	1.6	0
25	Isocitrate Dehydrogenase Mutations in Low-Grade Gliomas Correlate With Prolonged Overall Survival in Older Patients. <i>Neurosurgery</i> , 2019, 84, 519-528.	1.1	11
26	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	7.0	166
27	Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas. <i>Neurosurgery</i> , 2019, 85, E910-E916.	1.1	20
28	Long-term outcomes and late adverse effects of a prospective study on proton radiotherapy for patients with low-grade glioma. <i>Radiotherapy and Oncology</i> , 2019, 137, 95-101.	0.6	46
29	Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma. <i>OncolImmunology</i> , 2019, 8, e1577108.	4.6	35
30	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	7.0	26
31	Factors that modify the risk of intraoperative seizures triggered by electrical stimulation during supratentorial functional mapping. <i>Clinical Neurophysiology</i> , 2019, 130, 1058-1065.	1.5	22
32	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	3.7	16
33	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. <i>Neurosurgery</i> , 2019, 85, 204-210.	1.1	28
34	SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2016-2016.	1.6	14
35	(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas. <i>Translational Cancer Research</i> , 2019, 8, S167-S170.	1.0	22
36	Meningoencephalocele and Cerebrospinal Fluid Leak Complicating Orbital Decompression. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2018, 34, e79-e81.	0.8	6

#	ARTICLE	IF	CITATIONS
37	The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 41-47.	1.5	24
38	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. <i>Journal of Neurosurgery</i> , 2018, 128, 1123-1132.	1.6	37
39	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. <i>Neuro-Oncology</i> , 2018, 20, 44-54.	1.2	51
40	Neural encoding and production of functional morphemes in the posterior temporal lobe. <i>Nature Communications</i> , 2018, 9, 1877.	12.8	18
41	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	7.1	40
42	Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2041-2041.	1.6	3
43	HER2 positivity in brain metastases from gastrointestinal primary malignancies. <i>Journal of Clinical Oncology</i> , 2018, 36, 61-61.	1.6	1
44	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
45	Phantomia and Dysgeusia following Endoscopic Transcribriform Approaches to Olfactory Groove Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 38, 245-250.	0.8	7
46	NCCN Guidelines Insights: Bone Cancer, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 155-167.	4.9	204
47	Blockade of transforming growth factor- $\beta$ signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. <i>International Journal of Cancer</i> , 2017, 141, 2348-2358.	5.1	33
48	Vascularized Fibular Strut Autografts in Spinal Reconstruction after Resection of Vertebral Chordoma or Chondrosarcoma: A Retrospective Series. <i>Neurosurgery</i> , 2017, 81, 156-164.	1.1	23
49	EXTH-14. THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS AND POTENTIATES NAD <sup>+</sup> DEPLETION-MEDIATED CELL DEATH IN IDH1 MUTANT CANCERS. <i>Neuro-Oncology</i> , 2017, 19, vi75-vi75.	1.2	0
50	IMMU-64. TRIPLE COMBINATION IMMUNOTHERAPY WITH VACCINATION, PD-1 BLOCKADE, AND OX40 LIGATION IS HIGHLY EFFECTIVE AGAINST MURINE INTRACRANIAL GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, vi127-vi127.	1.2	0
51	IDH mutational status and the immune system in gliomas: a tale of two tumors?. <i>Translational Cancer Research</i> , 2017, 6, S1253-S1256.	1.0	13
52	Brachytherapy for Recurrent High-grade Meningiomas: An Institutional Experience. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, S1-S156.	0.8	0
53	Characterizing glioma microenvironment with ultra-high gradient diffusion MRI. <i>Journal of Clinical Oncology</i> , 2017, 35, 2050-2050.	1.6	0
54	An Algorithm for Surgical Approach to the Anterior Skull Base. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2016, 77, 364-370.	0.8	29

#	ARTICLE	IF	CITATIONS
55	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 4452-4465.	7.0	112
56	Aseptic Meningitis with Craniopharyngioma Resection: Consideration after Endoscopic Surgery. <i>Journal of Neurological Surgery Reports</i> , 2016, 77, e151-e155.	0.6	15
57	Perspectives on investigational drugs and immunotherapies for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1007-1009.	4.1	2
58	Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma. <i>Journal of Clinical Neuroscience</i> , 2016, 31, 99-105.	1.5	8
59	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	7.0	45
60	Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. <i>Neuro-Oncology</i> , 2016, 18, 863-872.	1.2	91
61	Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv310.	6.3	182
62	Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. <i>Journal of Neurosurgery</i> , 2016, 124, 106-114.	1.6	86
63	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	16.8	327
64	A Rare Finding of Schwannoma of the Vidian Canal: A Case Report. <i>Journal of Neurological Surgery Reports</i> , 2015, 76, e48-e51.	0.6	8
65	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
66	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	1.2	26
67	Immediate and Delayed Complications Following Endoscopic Skull Base Surgery. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2015, 76, 390-396.	0.8	43
68	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
69	Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2036-2036.	1.6	2
70	Esthesioneuroblastoma: An Update on the Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital Experience with Craniofacial Resection, Proton Beam Radiation, and Chemotherapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2014, 75, 058-064.	0.8	37
71	Comparative evaluation of methylene blue and demeclocycline for enhancing optical contrast of gliomas in optical images. <i>Journal of Biomedical Optics</i> , 2014, 19, 090504.	2.6	7
72	Delayed Endovascular Coil Extrusion following Internal Carotid Artery Embolization. <i>Journal of Neurological Surgery Reports</i> , 2014, 75, e255-e258.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Delayed Complications after Anterior Craniofacial Resection of Malignant Skull Base Tumors. Journal of Neurological Surgery, Part B: Skull Base, 2014, 75, 110-116.	0.8	15
74	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas. Clinical Cancer Research, 2014, 20, 2898-2909.	7.0	146
75	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. Cancer Discovery, 2014, 4, 1299-1309.	9.4	207
76	Postoperative Intensive Care Unit Requirements After Elective Craniotomy. World Neurosurgery, 2014, 81, 165-172.	1.3	73
77	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	1.5	21
78	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Neuroscience, 2014, 21, 1490-1496.	1.5	76
79	A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2014, 32, 2005-2005.	1.6	22
80	Targetable signaling pathway mutations and progression of <i>IDH</i> -mutant glioma.. Journal of Clinical Oncology, 2014, 32, 2061-2061.	1.6	0
81	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
82	Orbital Preservation in Patients with Esthesioneuroblastoma. Journal of Neurological Surgery, Part B: Skull Base, 2013, 74, 142-145.	0.8	10
83	Racial, Ethnic, and Socioeconomic Disparities in Patient Outcomes After Craniotomy for Tumor in Adult Patients in the United States, 1988â€“2004. Neurosurgery, 2010, 66, 427-438.	1.1	167
84	Racial, ethnic and socioeconomic disparities in the treatment of brain tumors. Journal of Neuro-Oncology, 2009, 93, 25-39.	2.9	116
85	Rapidly Rising Incidence of Cerebrospinal Fluid Shunting Procedures for Idiopathic Intracranial Hypertension in the United States, 1988â€“2002. Neurosurgery, 2005, 57, 97-108.	1.1	122
86	Craniotomy for meningioma in the United States between 1988 and 2000: decreasing rate of mortality and the effect of provider caseload. Journal of Neurosurgery, 2005, 102, 977-986.	1.6	103
87	Stereotactic interstitial radiosurgery for cerebral metastases. Journal of Neurosurgery, 2005, 103, 630-635.	1.6	27
88	Spinal epidural abscess: clinical presentation, management, and outcome. World Neurosurgery, 2005, 63, 364-371.	1.3	271